Cardiometabolic Health Congress

JULY 25, 2023

There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] Is the obesity paradox a real phenomenon?

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

Journal of the American Heart Association

MARCH 19, 2025

We aimed to examine the incidence of and risk factors for cardiotoxicity in a racially and ethnically diverse cohort with cancer treated with anthracyclines.MethodsWe included consecutive adult patients who underwent anthracyclinebased chemotherapy from 2016 to 2019 for any type of cancer. ResultsA total of 743 individuals were included (28.0%

Cancer 40

Cancer Risk Factors Obesity Heart Failure 40

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

x) from 2016‐2019. The rate of 30‐day readmission was overall stable (7.34% in 2016 and 7.70% in 2019; p=0.42), but the 90‐day readmission rate slightly increased from 11.69% in 2016 to 12.47% in 2019 (p=0.04). ConclusionThe annual rate of 90‐day readmission, but not 30‐day readmission, increased from 2016 to 2019.

Hemorrhage 40

Hemorrhage Coronary Artery Disease Obesity Heart Failure 40

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

x) from 2016‐2019 using the Nationwide Readmission Database (NRD). Data was weighted to allow for representative nationwide estimates.ResultsA total of 260,854 patients were admitted with a primary diagnosis of ICH between 2016‐2019. The mean age of the cohort was 68.49 years, with 52.6% being male.

Hemorrhage 40

Hemorrhage Risk Factors Coronary Artery Disease Obesity 40

Stroke Journal

JANUARY 30, 2025

we analyzed patients presenting from 2016 to 2021 with an initial diagnosis of stroke, defined by ICD-10 codes in any diagnostic position as abstracted from free text responses by ED staff. We therefore used population-level data to report the frequency of cardiac troponin assessments among U.S.

Stroke 40

Stroke Strokes Chest Pain Myocardial Infarction 40

Stroke Journal

FEBRUARY 1, 2024

Additionally, those with a history of kidney failure (2, 1.76 - 2.27), liver disease (1.32, 1.11 - 1.56), and heart failure (1.59, 1.35 - 1.86) had higher odds of experiencing MAVE. Patients were followed up for up to 24 weeks postpartum.

Inpatient 40

Inpatient Hypertension Document Obesity 40

EMS 12-Lead

JUNE 1, 2022

In isolation, however, syncope does not hold significant weight for OMI – as opposed to something like crushing chest discomfort, for example – although stereotypical ACS might become blurry in both the elderly and diabetic populations. Influence of left bundle branch block on long-term mortality in a population with heart failure.

Heart Failure 52

Heart Failure Myocardial Infarction Bradycardia Chest Pain 52

Dr. Paddy Barrett

AUGUST 15, 2023

Just for clarity, type 2 diabetes is when insulin resistance progresses to the point that your body can no longer keep your blood glucose levels under control. So if you have type 2 diabetes, you, by definition, are insulin resistant. For each additional feature, the likelihood and likely severity of insulin resistance increases.

Blood Pressure 52

Blood Pressure Risk Factors Diabetes Cholesterol 52

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Published Research kschukar Thu, 04/20/2023 - 11:12 Recently published (2016 – present) manuscripts utilizing STS data: Adult Cardiac Surgery, General Thoracic Surgery, Congenital Heart Surgery, and Intermacs/Pedimacs.

Research 52

Research Coronary Artery Bypass Graft Aortic valve Congenital 52

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Published Research kschukar Thu, 04/20/2023 - 11:12 Recently published (2016 – present) manuscripts utilizing STS data: Adult Cardiac Surgery, General Thoracic Surgery, Congenital Heart Surgery, and Intermacs/Pedimacs.

Research 52

Research Coronary Artery Bypass Graft Aortic valve Congenital 52

Dr. Malcolm Kendrick

OCTOBER 30, 2024

(2022-25) Swiss Reinsurance Company: £645K China Kadoorie Biobank (2002-ongoing) AstraZeneca: $300K Bayer AG: £300K GlaxoSmithKline: £3.6M Elinogrel feasibility trial (2010-2011) Novartis: £500K EMPA-KIDNEY (2017-ongoing) Boehringer Ingelheim: £106.3M Establishing Fuwai-Oxford research centre (2010-ongoing) Merck: £1.1M

Cholesterol 145

Cholesterol Article Research Diet 145